Sagimet Biosciences Inc. SGMT

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Our second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne.

The critical role of FASN overactivity in MASH makes it an attractive target for drug therapy. Our FASN inhibitor, denifanstat, targets multiple drivers of MASH by reducing steatosis, inflammation and fibrosis.

Last close 9.58 2026-10-23
Market cap $508.8M estimated share count
52-week range 4.50 - 11.45

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.58

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021
Revenue ——$2.0M——
R&D $39.1M$38.4M$19.8M$24.9M—
SG&A $17.8M$16.0M$13.0M$6.1M—
Total operating expenses $56.9M$54.5M$32.7M$31.1M—
Operating income -$56.9M-$54.5M-$30.7M-$31.1M—
Pre-tax income -$51.0M-$45.6M———
Income tax $0$0———
Net income -$51.0M-$45.6M-$27.9M-$30.5M—
EPS, basic -1.58-1.45-2.66-165.20—
EPS, diluted -1.58-1.45-2.66-165.20—
Shares, diluted (wtd. avg.) 32.3M31.4M10.5M184,619—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021
Cash and equivalents $35.0M$75.8M$75.1M$158.0K$56.7M
Short-term investments $78.1M$75.4M$19.8M$32.2M—
Total current assets $116.4M$152.8M$96.6M$32.8M—
Total assets $116.5M$160.3M$96.7M$33.0M—
Accounts payable $1.3M$1.4M$186.0K$1.1M—
Total current liabilities $5.1M$4.5M$5.7M$5.3M—
Total liabilities ——$5.7M$5.4M—
Retained earnings -$346.3M-$295.3M-$249.7M-$221.9M—
Total equity $111.4M$155.8M$91.1M-$186.9M-$158.3M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021
Operating cash flow -$45.6M-$42.4M-$23.8M-$24.5M—
Stock-based compensation $6.4M$5.3M$5.0M$1.9M—
Investing cash flow $4.6M-$61.7M$12.6M-$32.0M—
Financing cash flow $275.0K$104.8M$86.2M-$73.0K—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-026140.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -60M -40M -20M 0 20M Net income, FY2022: -30.5M Revenue, FY2023: 2M Net income, FY2023: -27.9M Net income, FY2024: -45.6M Net income, FY2025: -51M FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2021FY2022FY2023FY2024FY2025
Revenue — — $2.0M — —
Gross profit — — — — —
Net income — -$30.5M -$27.9M -$45.6M -$51.0M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Regulation FD disclosure Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%